Trial Profile
A randomised trial to investigate the effect of Elafin on myocardial injury and inflammation in coronary artery bypass surgery.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Tiprelestat (Primary)
- Indications Myocardial reperfusion injury
- Focus Proof of concept; Therapeutic Use
- Acronyms EMPIRE
- 26 Aug 2015 Results published in the Heart.
- 26 Aug 2015 Primary endpoint (Area under the curve (AUC) for plasma troponin I concentration over 48 hours.) has not been met as per results published in the Heart.
- 13 Mar 2015 Interim results (significant reduction in troponin I after 6 hours) published in Proteo, Inc Media Release.